Table 1. Patients' characteristics and MRI findings.
PSA: prostate-specific antigen, PI-RADS: Prostate Imaging Reporting and Data System, DWI: diffusion-weighted imaging, ADC: apparent diffusion coefficient, DCE: dynamic contrast enhanced
| Patient | Age (years) | PSA (ng/mL) | Prostate volume (cc) | PSA density (ng/mL²) | Location | PI-RADS | Shape | Size (mm) | T2 | DWI | ADC map | DCE |
| 1 | 60 | 5.94 | 40 | 0.149 | Peripheric zone | 5 | Pseudo-nodular | 8 | Hypointensity | Hypersignal | Hyposignal | No enhancement |
| 2 | 64 | 9.75 | 144 | 0.068 | Peripheric zone | 4 | Not defined | 10 | Intermidium Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 3 | 60 | 9.73 | 58 | 0.168 | Peripheric zone | 4 | Nodular | 10 | Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 4 | 62 | 8.59 | 56 | 0.153 | Transition zone | 4 | Non-circumscribed | 8 | Intermidium Hypointensity | Hypersignal | Hyposignal | No enhancement |
| 5 | 46 | 7.26 | 35 | 0.207 | Peripheric zone | 4 | Nodular | 10 | Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 6 | 61 | 4.95 | 66 | 0.075 | Peripheric zone | 5 | Nodular | 15 | Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 7 | 70 | 7.32 | 75 | 0.098 | Peripheric zone | 5 | Nodular | 18 | Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 8 | 65 | 4.60 | 35 | 0.131 | Peripheric zone | 4 | Nodular | 6 | Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 9 | 72 | 5.78 | 64 | 0.090 | Transition zone | 4 | Non-circumscribed | 8 | Hypointensity | Hypersignal | Hyposignal | No enhancement |
| 10 | 59 | 9.54 | 55 | 0.173 | Peripheric zone | 5 | Nodular | 15 | Hypointensity | Hypersignal | Hyposignal | Focal enhancement |
| 11 | 68 | 7.18 | 92 | 0.078 | Peripheric zone | 4 | Nodular | 10 | Intermidium hypointensity | Hypersignal | Hyposignal | No enhancement |
| 12 | 75 | 11.20 | 110 | 0.102 | Transition zone | 4 | Lenticular | 10 | Hypointensity | Hypersignal | Hyposignal | No enhancement |